Arndt Vogel retweeted
Thank you Colleagues for a phenomenal #ESMO26
ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME.
📣 101.7M impressions of potential reach
💬 6.1K posts on X from 988 participants in 34 countries
⚡ 43.1 posts per hour across the meeting days
😊 45% positive sentiment, with only 6% negative
Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO
🏆 Top influencers
@DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista
🌎 Where the conversation came from
North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities.
🔬 Top studies by impact
1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts
2️⃣ VOLGA (bladder): 3.7M reach, 141 posts
3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach
4️⃣ SAFFRON (NSCLC): 3.3M reach
5️⃣ INTerpath-001 (melanoma): 154 posts
Pinging our Collaborators
Pivotal Phase 2 study of derazantinib for previously-treated CCA with FGFR2 aberrations: FIDES-01
@HEP_Journal
doi.org/10.1097/HEP.00000000…
👉ORR 22%, DCR 72%, mPFS 8.2 mo, mOS 17.2 mo
👉some efficacy in mut/amp GA
🧐Overall consistency, and Pemi, Futi & Lira approved
@myESMO @ASCO @EASLnews @ILCAnews
s.c envafolimab + GEMOX vs GEMOX alone as 1L treatment for BTC in Chinese patients: A randomized, ph III trial
#ESMO26 #ESMOAmbassadors
👉ORR: 27 vs 20%
👉 mPFS: 5.4 vs 4.5 mo
👉 mOS: 10.9 8.6 mo
🧐Confirms KN-966 & TOPAZ-1 in 🇨🇳pts
@myESMO @ASCO
OPTIMUM: phase 2 study of maintenance olaparib +/-Durva in DDR gene-mutated aBTC
#ESMO26 #ESMOAmbassadors
👉ORR 44% response during induction CTx
👉ORR 39% vs 25%
👉 6mo PFS-rate : 62 vs 62%
👉 mOS: 16 vs 29 mo
🧐Neg study, but very promising signal, requires further investigations
@myESMO @ASCO
Phase I study of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in HCC: Updated results
#ESMO26 #ESMOAmbassadors
👉ORR: 40.4%, all PR, DCR 94%
👉mOS: 18 mo
🧐Impressive response, and interesting OS, needs confirmation in western populations
@myESMO @ASCO
LEAP-012 study of lenvatinib + pembrolizumab vs plc with TACE for HCC: Long-term OS results
#ESMO26 #ESMOAmbassadors
👉ORR: 48 vs 33.7%
👉 mPFS: 14.6 vs 10.2 mo
👉 mOS: 40.4 vs 40.8 mo
🧐 Higher ORR & PFS did not translate into OS, a bit disappointing
@myESMO @ASCO
Safety & efficacy of INCB161734, a oral KRAS G12D inh, in combination with GEMNab or FOLFIRINOX in mPDAC
#ESMO26 #ESMOAmbassadors
👉ORR: 69 vs 89%, no PD
👉mPFS:
👉GI & hemato toxicity, but no skin tox
🧐very impressive, combination with both CTx feasible, ph 3 ongoing
@myESMO @ASCO
HRS-4642 plus CTx ± adebrelimab as perioperative therapy in KRAS G12D-mPDAC: Preliminary results of a phase 2 study
#ESMO26 #ESMOAmbassadors
👉ORR: 63 vs 87%
👉Manageable safety
🧐 exciting results, tumor shrinkage in all pts, added benefit of ICI remains to be seen
@myESMO @ASCO
🔥Presidential session at ESMO 2026 🔥
HARMONi-GI1 ph-3: Ivonescimab + CTx vs durvalumab + CTx as 1L for BTC
#ESMO26 #ESMOAmbassadors
👉ORR: 53.8 vs. 32.5 %
👉mPFS: 8.4 vs 5.8 mo
👉mOS: 14.9 vs. 12.1 mo
🧐 Very promising Chinese data, would be great to see data in a global population
@myESMO @ASCO
🔥Presidential session at ESMO 2026 🔥
CLARITY-Gastric 01: Ph 3 of sonesitatug vedotin in 2L+ CLDN18.2-positive GEC
#ESMO26 #ESMOAmbassadors
👉ORR: 23 vs 13%
👉mPFS: 4.2 vs 3.8 mo
👉mOS: 10 vs 5 mo
👉No new safety signals
🧐 exciting results, new option for 2L+ CLDN18.2+ pts
@myESMO @ASCO
DFS and OS after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
@TheLancet
doi.org/10.1016/S0140-6736(2…
👉💯% DFS
👉💯% OS
👏does not need any comment
@myESMO @ASCO
Final OS results from CheckMate 8HW: Nivo plus ipi vs nivo or CTx in MSI-H/dMMR mCRC
#ESMO26 #ESMOAmbassadors
👉ORR 72% 58%
👉mOS: NR --> NI vs N HR 0.66
👉5-yr for Nivo/Ipi: 77%
🧐Convincing, Nivo + Ipi as SOC in 1L MSI CRC
@myESMO @ASCO
Biweekly vs conventional trifluridine/tipiracil plus bevacizumab for refractory mCRC: The pragmatic ph 3 PRABITAS trial
#ESMO26 #ESMOAmbassadors
👉ORR: 2 vs 2%
👉 mPFS: 3.9 vs 3.9 mo
👉 mOS: 10.3 vs 11.3 mo
🧐similar efficacy, less toxicity, supports biweekly schedule
@myESMO @ASCO
Long-term follow-up of Temab-A with Bev vs SOC in 3L+ CRC: Updated results of a ph 1
#ESMO26 #ESMOAmbassadors
👉 mPFS: 6.8 vs 4.2 mo
👉 mOS: 14.7 vs 10.2 mo
👉 manageable safety
🧐Promising, ph-3 ongoing
@myESMO @ASCO
Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC
#ESMO26 #ESMOAmbassadors
👉ORR: 25% vs 50%, DCR: 75 vs 90%
👉 no new safety signals
🧐Supports the combination with CTx
@myESMO @ASCO
TRIDENTE: A phase II study of rechallenge with ENCO, BINI, and CET in BRAF V600E-mutant mCRC
#ESMO26 #ESMOAmbassadors
👉mPFS: 2.8 mo
👉mOS: 9.6 mo
👉ORR: 19%
🧐Supports biomarker-driven re-challenging concepts for 🎯therapies in CRC
@myESMO @ASCO
Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse phase II trial
#ESMO26 #ESMOAmbassadors
👉 mPFS: 7.1
👉 mOS: NR
👉ORR 15%
🧐Interesting signal to continue EC, more translational data would be great
@myESMO @ASCO
Phase I study of BGB-B2033 (GPC3 x 4-1BB bispecific AB): Dose optimization and escalation update in advanced HCC
#ESMO26 #ESMOAmbassadors
👉ORR: 30%
👉manageable safety
🧐very promising agent, looking forward to see combination with ICI
@myESMO @ASCO
Liver function trajectory & post-progression outcomes in the pts 3 EMERALD-3 study of STRIDE ± Lenva + TACE in HCC
#ESMO26 #ESMOAmbassadors
👉 liver function maintained
👉 similar subsequent therapies
🧐No overal OS benefit, but interesting OS signal for STRIDE in ALBI 1 pts
@myESMO @ASCO

































































